The scandal of unreported trials has been known about for decades, prompting a variety of initiatives, legislative changes and campaigns. Sophie Fessl asks what impact these have had on reporting practices, and how far patients [more]
As a journalist, I often wonder about the exact location of the fine line that separates justified enthusiasm from self-serving hype, especially when it comes to clinical trials. Last week, I asked the question of [more]
«We must abandon the fiction that current oversight systems are adequate to protect volunteers in first-in-human trials or to steward scientific efforts»: this is the strong conclusion of a paper published in Nature by two [more]
Starting next year, trial sponsors can negotiate ethical approval in a member state of their choice, and have the same terms applied across all EU countries. Daniela Ovadia looks at the implications of the new regulation [more]
The concept is attractive, the results in some patients have been stunning, but what will it take to extend these impressive responses to wider groups of patients? Peter McIntyre reports. There is a growing sense [more]
Karol Sikora, a medical oncologist who has directed cancer services at a major London hospital, triggered an angry reaction earlier this year when he suggested that younger patients should have priority when it comes to [more]
Joining a clinical trial can be a lifeline for patients with few options open to them. But are outdated attitudes and practices preventing them from benefiting as much as they could? The transformation in the [more]
Patients are losing out because the rules governing research are designed to restrain rather than facilitate. Its got to change, says Roger Stupp, who is frustrated that 10 years after helping set a new standard [more]
A single infrastructure for Europe’s rapidly evolving biobanks is urgently needed. But finding agreement on the ethics, language and operating standards is proving quite a challenge. Download full article